hVIVO plc (AIM & Euronext: HVO) , (formerly Open Orphan plc) a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that Dr Andrew Catchpole, Chief Scientific Officer, will be delivering a presentation at the World Vaccine Congress, Washington D.C., United States. Full details of the presentation are included below:
Next week brings the biggest vaccine conference of the year, the World Vaccine Congress in Washington, where all drug developers of all stages from around the world will be in attendance to meet with potential partners and service providers. Dr Andrew Catchpole will be speaking at the event; entitled Challenge Studies – can the results be expected to mimic field trial data?
These conferences offer excellent opportunities for our BD team to continue discussions with potential clients and raise awareness of challenge trials and our world-leading services with new potential customers.
Challenge Studies – can the results be expected to mimic field trial data?
Date/Time
Wednesday 5 April 2023, 17.10 (ET)
The World Vaccine Congress will take place at the Walter E. Washington Convention Center in Washington D.C. between 3-6 April 2023. hVIVO will be at booth 813 during the congress for potential partnering discussions.
The World Vaccine Congress, organised by Terrapin, is the largest and most established meeting dedicated to vaccines and has run for 23 years. From basic research to commercial manufacture, the event covers the whole vaccine value chain, with hundreds of speakers and thousands of attendees from leading global vaccines developers, academia and policymakers.
More information about the event, including attendance, can be found here .
To request meetings with hVIVO at the World Vaccine Congress, interested parties should register with Swapcard and use the following link or by emailing [email protected]
Yamin ‘Mo’ Khan, Chief Executive Officer at hVIVO, said: “I am delighted that Andrew will be presenting at the largest vaccine event of the year amongst many other notable speakers, discussing the significant value of human challenge trial data . As the global leader in conducting human challenge trials to test vaccines and antivirals for infectious and respiratory diseases, we are looking forward to participating in roundtable discussions and sharing insights into how human challenge trials can accelerate the drug development process.”
For further information please contact:
hVIVO plc
+44 (0) 20 7756 1300
Yamin ‘Mo’ Khan, Chief Executive Officer
Stephen Pinkerton, Chief Financial Officer
